Tesofensine
| Code | Size | Price |
|---|
| TAR-T28951-50mg | 50mg | £837.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28951-100mg | 100mg | £1,267.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Tesofensine, a serotonin?noradrenaline?dopamine reuptake inhibitor, is used potentially for the treatment of obesity.
CAS:
195875-84-4
Formula:
C17H23Cl2NO
Molecular Weight:
328.28
Purity:
0.98
SMILES:
[H][C@]12CC[C@]([H])([C@H](COCC)[C@H](C1)c1ccc(Cl)c(Cl)c1)N2C
References
1. Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacol Biochem Behav. 2013 Sep;110:265-71. doi: 10.1016/j.pbb.2013.07.018. PubMed PMID: 23932919.
2. Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring). 2013 May;21(5):985-92. doi: 10.1002/oby.20122. PubMed PMID: 23784901.
3. van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. Eur Neuropsychopharmacol. 2012 Apr;22(4):290-9. doi: 10.1016/j.euroneuro.2011.07.015. PubMed PMID: 21889317.
4. Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010 Jul;88(1):69-78. doi: 10.1038/clpt.2010.67. PubMed PMID: 20520602.